Elixinol: “Majority of Hemp-Based CBD Sellers Will Disappear”

Marijuana Business Daily’s John Schroyer shared an extensive review of the CBD from Industrial Hemp market, discussing its growth as well as an outlook for the industry. His article included commentary from Bluebird Botanicals, Colorado CultivarsElixinol and HempMeds, a division of Medical Marijuana, Inc. (OTC: MJNA).

Gabe Ettenson, Co-founder of Elixinol, pointed to the market being very crowded, a point reiterated by Rick Trojan who suggested that white labeling, a process where CBD sellers buy from bulk producers and then resell to end consumers, has contributed to the growth of suppliers. Ettenson suggests that a shake-out is ahead due to the changing regulations that will favor companies with a scientific approach.

Our primary focus right now is to identify sort of that sweet spot where we believe the industry is headed, which is somewhere between a heavily regulated FDA nutraceutical company, and a sub-pharmaceutical company.

Gabe Ettenson, Co-founder of Elixinol

A majority of companies … will be gone, and the ones that survive will support the product with science.

Schroyer points to some of the issues with which the industry contends, including a lack of clarity about domestic sourcing and trouble with credit card processing. At the same time, he points to a growing international market that could benefit the industry.

Read John Schroyer’s “Hemp-based CBD market continues its enormous growth”: https://mjbizdaily.com/growth-spurts-continue-for-hemp-based-cbd-market/

Published by Alan Brochstein, CFA
Alan Brochstein, CFA
Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email

Get Our Sunday Newsletter